ArticleBioinformation2020
CoViD-19 Immunopathology and Immunotherapy.
Article in Bioinformation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04798716 (Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19 Positive Patients With Acute Respiratory Distress Syndrome and/or Novel Coronavirus Pneumonia), which is not on this map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19 Positive Patients With Acute Respiratory Distress Syndrome and/or Novel Coronavirus Pneumonia
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- Post-acute CoVid-19 syndrome (PACS) linked cardiovascular symptoms.Bioinformation · 2024Article
- Article
- SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.Cell death & disease · 2023Review
- Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines.Vaccines · 2023Review
- Permafrost viremia and immune tweening.Bioinformation · 2023Article
- Colliding Pandemics and CoViD-19.Bioinformation · 2023Article
- Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients.PloS one · 2023Article
- CD4+ T Cell Regulatory Network Underlies the Decrease in Th1 and the Increase in Anergic and Th17 Subsets in Severe COVID-19.Pathogens (Basel, Switzerland) · 2022Article
- Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities.Clinical immunology (Orlando, Fla.) · 2022Review
- The Impact of COVID-19 on the Quality of Life and Happiness of Care Home Residents in Croatia: A Cross-Sectional Study.Behavioral sciences (Basel, Switzerland) · 2022Article
- Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report.Immunotherapy · 2022Article
- Premenopausal and postmenopausal women during the COVID-19 pandemic.Przeglad menopauzalny = Menopause review · 2022Review
- NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.Cell biochemistry and function · 2022Review
- SARS-CoV-2 triggering autoimmune diseases.Cytokine · 2022Review
- Review
- Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.Journal of infection and public health · 2022Review
- Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.Frontiers in immunology · 2022Review
- Ramelteon, as a Melatonin Agonist, is Expected to be Effective on COVID-19 Induced Organ Damage: The Hypothetic Role of NF-κB Signaling Pathway.Advanced biomedical research · 2022Article
- Post acute CoViD-19 syndrome (PACS) - Long CoViD.Bioinformation · 2022Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New evidence on the T-cell immuno-pathology in patient's with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief, notable T cytopoenia was recorded by flow cytometry in the CD4+ and the CD8+ populations, which were significantly yet inversely correlated with remarkably increased serum levels of the pro-inflammatory cytokines IL-6, IL-10 and TNF-a. Flow cytometry established a progressive increase in the expression of programmed cell death marker-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) as patients (n=14) deteriorated from prodromal to symptomatic CoViD-19 requiring intensive care. Here, we interpret these observations of Diao et al from our current understanding of T cell immunophysiology and immunopathology following an immune challenge in the form of sustained viral infection, as is the case in CoViD-19, with emphasis on exhausted T cells (Tex). Recent clinical trials to rescue Tex show promising outcomes. The relevance of these interventions for the prevention and treatment of CoViD-19 is discussed. Taken together, the data of Diao et al could proffer the first glimpse of immunopathology and possible immunotherapy for patients with CoViD-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.